<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03388788</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00017489</org_study_id>
    <nct_id>NCT03388788</nct_id>
  </id_info>
  <brief_title>Body Weight, Sleep, and Heart Health</brief_title>
  <official_title>Circadian Mechanisms of Cardiovascular Risk in Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multidisciplinary investigation examining the circadian mechanisms regulating
      cardiovascular (CV) risk in obesity. Specifically, in a valid circadian protocol, the
      investigators aim to study resting cardiovascular risk markers and the reactivity of
      circadian rhythms in these risk markers to standardized stressors in obesity. Furthermore,
      using an ingenious approach, the investigators propose to explore impairment in pre/post
      synaptic function in the cardiac left ventricle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overall, these studies will help us answer whether CV rhythms predispose obese individuals to
      increased CV disease risk - particularly around the vulnerable morning period. The results
      will serve as a foundation for clinical trials of appropriately timed dosing of medications
      targeting aspects of the CV system in obesity that increase effectiveness while decreasing
      side-effects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>5 Days</time_frame>
    <description>Beat-by-beat and ambulatory blood pressure measurements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>5 Days</time_frame>
    <description>Heart rate via 2-channel echocardiogram (ECG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epinephrine</measure>
    <time_frame>5 days</time_frame>
    <description>Venous Epinephrine to estimate sympathetic output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Norepinephrine</measure>
    <time_frame>5 days</time_frame>
    <description>Venous Norepinephrine to estimate sympathetic output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol</measure>
    <time_frame>5 days</time_frame>
    <description>Saliva cortisol to estimate sympathetic output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldosterone</measure>
    <time_frame>5 days</time_frame>
    <description>Venous Aldosterone to estimate sympathetic output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocannabinoid</measure>
    <time_frame>5 days</time_frame>
    <description>Plasma endocannabinoid to estimate sympathetic regulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability (HRV)</measure>
    <time_frame>5 days</time_frame>
    <description>Analysis of HRV from 12-lead ECG to assess parasympathetic activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>malondialdehyde (MDA) adducts</measure>
    <time_frame>5 days</time_frame>
    <description>Plasma MDA to measure oxidative stress and inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow Mediated Dilation (FMD)</measure>
    <time_frame>5 days</time_frame>
    <description>FMD to measure endothelial function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Necrosis Factor alpha (TNF-alpha)</measure>
    <time_frame>5 days</time_frame>
    <description>TNF-alpha to assess inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary blood flow</measure>
    <time_frame>5 days.</time_frame>
    <description>Radiolabeled water (O15-water) to measure coronary blood flow during PET Imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Norepinephrine reuptake transport</measure>
    <time_frame>5 days.</time_frame>
    <description>Radiolabeled meta-hydroxyephedrine (11C-mHED) to measure norepinephrine reuptake during PET Imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-adrenergic receptor density</measure>
    <time_frame>5 days.</time_frame>
    <description>Radiolabeled agonist (11C-CGP12177) to measure beta-adrenergic receptors during PET Imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dual Emission X-ray Absorbance (DEXA) Body composition</measure>
    <time_frame>1 day</time_frame>
    <description>DEXA imaging to assess body composition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary Artery Calcium Score</measure>
    <time_frame>1 scan.</time_frame>
    <description>Coronary Calcium Computed Tomography (CT) Scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary Microvascular Blood Flux</measure>
    <time_frame>3 days</time_frame>
    <description>1. Determine in lean healthy humans if coronary microvascular function, measured as coronary microvascular blood flux, has an endogenous circadian rhythm with lowest function in the morning. 2. Test the hypothesis that people with obesity have impaired coronary microvascular blood flux compared to lean individuals, with the exaggerated impairment during the morning. Measured using myocardial contrast echocardiography.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Cardiovascular Risk Factor</condition>
  <condition>Circadian Dysregulation</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Normal Weight</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy lean controls [18.5&lt;BMI&lt;25 kg/m2 and WC &lt;94/80 (men and women respectively)] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Overweight</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy obese [30≤BMI&lt;40 and waist circumference (WC) ≥94/80 (men and women respectively)] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET Imaging</intervention_name>
    <description>Positron Emission Tomography (PET) imaging for research.</description>
    <arm_group_label>Normal Weight</arm_group_label>
    <arm_group_label>Overweight</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Circadian Study Protocol</intervention_name>
    <description>5-day circadian study schedule</description>
    <arm_group_label>Normal Weight</arm_group_label>
    <arm_group_label>Overweight</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>11C-Meta-Hydroxyephedrine (mHED)</intervention_name>
    <description>11C-meta-hydroxyephedrine will be used during PET imaging to measure cardiac presynaptic norepinephrine transporter function.</description>
    <arm_group_label>Normal Weight</arm_group_label>
    <arm_group_label>Overweight</arm_group_label>
    <other_name>11C-mHED</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>11C-CGP12177</intervention_name>
    <description>Cardiac beta adrenergic receptor density will be measured via PET imaging with infusion of 11C-CGP12177.</description>
    <arm_group_label>Normal Weight</arm_group_label>
    <arm_group_label>Overweight</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>O15-water</intervention_name>
    <description>Blood flow will be measured via PET imaging with infusion of O15-water.</description>
    <arm_group_label>Normal Weight</arm_group_label>
    <arm_group_label>Overweight</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 25-65

          -  Lean and overweight (BMI 18.5-40kg/m2)

          -  Habitually sedentary

        Exclusion Criteria:

          -  History of smoking/tobacco use

          -  Insomnia

          -  Moderate to severe obstructive sleep apnea.

          -  Prior shift work within 6 months prior to the study.

          -  Prescription medications

          -  Drugs of abuse

          -  Acute, chronic, or debilitating medical condition (including diabetes, hypertension,
             and metabolic syndrome)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A Shea, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Institute of Occupational Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeanne M Link, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Center for Radiochemistry Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew W McHill, PhD</last_name>
    <phone>5033463808</phone>
    <email>circadian@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Chess, BS/BA</last_name>
    <phone>5854904146</phone>
    <email>circadian@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew W McHill, PhD</last_name>
      <phone>503-494-2594</phone>
      <email>mchill@ohsu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Steven A. Shea</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronobiology Disorders</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>CGP 12177</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

